All Releases
 |
BioCryst Receives First Peramivir Order From U.S. Government
Nov 5, 2009
|
11.2 KB |
| |
BIRMINGHAM, Ala., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health...
|
|
BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan
Nov 4, 2009
|
12.7 KB |
| |
BIRMINGHAM, Ala., Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this...
|
|
BioCryst to Present at Oppenheimer Healthcare Conference
Oct 29, 2009
|
8.3 KB |
| |
BIRMINGHAM, Ala., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the Oppenheimer & Co., Inc. 20th Annua...
|
|
BioCryst Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Oct 29, 2009
|
19.5 KB |
| |
BIRMINGHAM, Ala., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
"BioCryst ...
|
|
Emergency Use Authorization Granted For BioCryst's Peramivir
Oct 23, 2009
|
11.5 KB |
| |
BIRMINGHAM, Ala., Oct 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigatio...
|
|
BioCryst Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
Oct 22, 2009
|
8.7 KB |
| |
BIRMINGHAM, Ala., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its third quarter 2009 financial results will be released on Thursday, October 29, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and to p...
|
|
BioCryst to Present at JMP Securities Healthcare Conference
Oct 2, 2009
|
8.3 KB |
| |
BIRMINGHAM, Ala., Oct 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the JMP Securities Healthcare Focus Con...
|
|
BioCryst Clarifies Government Declaration Regarding Peramivir
Oct 2, 2009
|
11.0 KB |
| |
BIRMINGHAM, Ala., Oct 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Office of the Secretary, Department of Health & Human Services (HHS) has issued "HHS Secretary's Declaration for the Use of the Public Readiness and Emergency Preparedness Act for the Influenza Anti...
|
|
BioCryst Provides Update Regarding Peramivir for Influenza
Sep 30, 2009
|
13.4 KB |
| |
BIRMINGHAM, Ala., Sept 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peram...
|
|
BioCryst Announces Initiation of Phase 2 Study of BCX4208 for the Treatment of Gout
Sep 28, 2009
|
11.8 KB |
| |
BIRMINGHAM, Ala., Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on ...
|
|
BioCryst Receives Peramivir Request for Proposal From the U.S. Government
Sep 21, 2009
|
10.3 KB |
| |
BIRMINGHAM, Ala., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patien...
|
|
BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza
Sep 21, 2009
|
12.7 KB |
| |
BIRMINGHAM, Ala., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (...
|
|
BioCryst to Present at UBS Global Life Sciences Conference
Sep 17, 2009
|
8.1 KB |
| |
BIRMINGHAM, Ala., Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, plans to provide a corporate summary at the UBS Global Life Sciences Conference in New York on Monday, September 21, 2009 at 3:00 p...
|
|
BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
Sep 15, 2009
|
12.9 KB |
| |
BIRMINGHAM, Ala., Sept 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and di...
|
|
BioCryst Executives to Present at Two Investor Conferences
Sep 8, 2009
|
8.4 KB |
| |
BIRMINGHAM, Ala., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that executives plan to provide corporate summaries at two upcoming investor conferences.
Dr. William P. Sheridan, Chief Medical Officer of BioCryst is scheduled to present a corporate summary at the Rodma...
|
|
BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
Jul 30, 2009
|
17.1 KB |
| |
BIRMINGHAM, Ala., July 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter and six months ended June 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir in the U.S.
"Our...
|
|
BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Jul 28, 2009
|
8.4 KB |
| |
BIRMINGHAM, Ala., July 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2009 financial results will be released on Thursday, July 30, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and provi...
|
|
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
Jul 17, 2009
|
12.3 KB |
| |
BIRMINGHAM, Ala., July 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co., Ltd. of Osaka, Japan and conducted ...
|
|
BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
May 14, 2009
|
11.3 KB |
| |
BIRMINGHAM, Ala., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced long-term data from a Phase 2 study of forodesine, the Company's lead oncology compound, in patients with cutaneous T-cell lymphoma (CTCL). The data will be presented at the 45th Annual Meeting of the American So...
|
|
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
May 8, 2009
|
17.2 KB |
| |
BIRMINGHAM, Ala., May 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its inventory of finished pera...
|
|
|
